CAMP
Camp4 Therapeutics Corp
NASDAQ · Healthcare · Biotechnology · US
$4.24
+5.21%6
Insider buys (3m)
6
Insider sells (3m)
-$2.4M
Net value (3m)
-3.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Gold Kelly · officer: Chief Financial Officer | Purchase | 10,000 | $3.96 |
| Aug 31, 2026 | Schwab Andrew J. · director | Sale | 400,000 | $4.04 |
| Aug 26, 2026 | Schwab Andrew J. · director | Sale | 10 | $4.50 |
| Aug 21, 2026 | Schwab Andrew J. · director | Sale | 45,147 | $4.76 |
| Aug 21, 2026 | Schwab Andrew J. · director | Sale | 32,018 | $4.50 |
| Aug 21, 2026 | Schwab Andrew J. · director | Sale | 114,700 | $4.54 |
| Aug 19, 2026 | Tardiff Daniel · officer: Chief Scientific Officer | Sale | 1,738 | $4.76 |
| Aug 5, 2026 | Young Richard A · director | Purchase | 16,378 | $1.65 |
| Aug 5, 2026 | 5AM Partners VI, LLC · 10 percent owner | Purchase | 3,179,558 | $0.00 |
| Aug 5, 2026 | Gold Kelly · officer: Chief Financial Officer | Purchase | 6,551 | $1.65 |
| Aug 5, 2026 | Maricich Yuri · officer: Chief Medical Officer | Purchase | 6,551 | $1.65 |
| Aug 5, 2026 | Mandel-Brehm Josh · director, officer: Chief Executive Officer | Purchase | 6,551 | $1.65 |
| Aug 5, 2026 | Schwab Andrew J. · director | A-Award | 3,179,558 | $0.00 |
| Jun 12, 2026 | WILLIAMS DOUGLAS E · director | A-Award | 28,000 | $4.34 |
| Jun 12, 2026 | Nashat Amir · director, 10 percent owner: | A-Award | 28,000 | $4.34 |
| Jun 12, 2026 | Holtzman Steven H · director | A-Award | 28,000 | $4.34 |
| Jun 12, 2026 | Young Richard A · director | A-Award | 28,000 | $4.34 |
| Jun 12, 2026 | Stewart Murray · director | A-Award | 28,000 | $4.34 |
| Jun 12, 2026 | Schwab Andrew J. · director, 10 percent owner: | A-Award | 28,000 | $4.34 |
| Apr 3, 2026 | Maricich Yuri · officer: Chief Medical Officer | A-Award | 215,000 | $4.46 |
| Apr 3, 2026 | Tardiff Daniel · officer: Chief Scientific Officer | A-Award | 170,000 | $4.46 |
| Apr 3, 2026 | Gold Kelly · officer: Chief Financial Officer | A-Award | 215,000 | $4.46 |
| Apr 3, 2026 | MacLean Michael F · director | A-Award | 56,000 | $4.46 |
| Apr 3, 2026 | Mandel-Brehm Josh · director, officer: Chief Executive Officer | A-Award | 580,000 | $4.46 |
| Dec 22, 2025 | Gold Kelly · officer: Chief Financial Officer | A-Award | 190,000 | $6.01 |
| Dec 22, 2025 | Maricich Yuri · officer: Chief Medical Officer | A-Award | 190,000 | $6.01 |
| Dec 22, 2025 | Tardiff Daniel · officer: Chief Scientific Officer | A-Award | 145,500 | $6.01 |
| Dec 22, 2025 | Mandel-Brehm Josh · director, officer: Chief Executive Officer | A-Award | 425,000 | $6.01 |
| Sep 15, 2025 | 5AM Partners VI, LLC · 10 percent owner | Purchase | 2,941,176 | $1.53 |
| Sep 15, 2025 | Schwab Andrew J. · director, 10 percent owner: | A-Award | 2,941,176 | $1.53 |
Institutional positioning
13F filings over the trailing two quarters
New 38Increased 31Reduced 21Sold out 8
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Jupiter Topco LLC | New Position | 6,307,636 | Aug 14, 2026 |
| JANUS HENDERSON GROUP PLC | Unchanged | 6,307,636 | May 18, 2026 |
| 5AM VENTURE MANAGEMENT, LLC | Unchanged | 5,869,091 | May 15, 2026 |
| 5AM Venture Management, LLC | Unchanged | 5,869,091 | Aug 14, 2026 |
| FMR LLC | Increased | 4,933,432 | May 15, 2026 |
| FMR LLC | Reduced | 4,904,339 | Aug 13, 2026 |
| VIVO CAPITAL, LLC | Unchanged | 4,246,568 | May 20, 2026 |
| Vivo Capital, LLC | Unchanged | 4,246,568 | Aug 14, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 2,632,437 | May 15, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Reduced | 2,575,724 | Aug 14, 2026 |
| ENAVATE SCIENCES GP, LLC | Reduced | 2,190,920 | May 15, 2026 |
| AH CAPITAL MANAGEMENT, L.L.C. | Unchanged | 2,125,339 | May 15, 2026 |
| a16z Capital Management, L.L.C. | Unchanged | 2,125,339 | Aug 14, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Reduced | 1,960,784 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Unchanged | 1,960,784 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 2, 2026